Psychometric validation of anti-clot treatment scale and treatment satisfaction questionnaire for medication version II in Japanese patients with atrial fibrillation

Watanabe-Fujinuma, Emi; Banderas, Benjamin; Koretsune, Yukihiro; Kumagai, Koji; Uchiyama, Shinichiro; Yamashita, Takeshi; Yasaka, Masahiro; Akiyama, Sayako; Brière, J; Dickie, Gavin; Cano, Stefan

doi:10.1080/13696998.2019.1609003

Cited by 3 publications

(3 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1 ). The TSQM-II is an 11-item, self-administered, psychometrically valid measure of patient-reported satisfaction with medication [ 16 ] and has demonstrated validity and reliability among Japanese patients with chronic diseases [ 17 ]. The TSQM-II comprises the following four domains: effectiveness, side effects, convenience, and global satisfaction.…”

Section: Methodsmentioning

confidence: 99%

Treatment satisfaction with molidustat in CKD-related anemia in non-dialysis patients: a post-hoc analysis of two clinical trials

et al. 2023

View full text Add to dashboard Cite

Background Erythropoiesis-stimulating agents (ESAs) are the standard treatment for patients with renal anemia to increase hemoglobin (Hb) levels and reduce the need for blood transfusions. However, treatments targeting high Hb levels require high doses of ESAs administered intravenously, which is associated with an elevated risk of adverse cardiovascular events. Furthermore, there have been some problems such as hemoglobin variability and low achievement of target hemoglobin due to the shorter half-lives of ESAs. Consequently, erythropoietin-promoting medications, such as hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitors, have been developed. This study aimed to evaluate changes in the Treatment Satisfaction Questionnaire for Medicine version II (TSQM-II) domain scores relative to baseline in each trial, to assess patient satisfaction with molidustat versus darbepoetin alfa. Methods This post-hoc analysis of two clinical trials compared treatment satisfaction with an HIF-PH inhibitor, molidustat, versus a standard ESA, darbepoetin alfa, as part of therapy in patients with non-dialysis chronic kidney disease (CKD) and renal anemia. Results Exploratory outcome data using the TSQM-II showed that both arms in both trials had enhanced treatment satisfaction over the course of the study period, as well as improvements in most TSQM-II domains at week 24 of treatment. Molidustat was associated with convenience domain scores at multiple time points depending on the trial. More patients were highly satisfied with the convenience of molidustat than that of darbepoetin alfa. Patients treated with molidustat had increased global satisfaction domain scores compared with those treated with darbepoetin alfa; however, the differences in global satisfaction domain scores were not significant. Conclusion These patient-reported satisfaction outcomes support the use of molidustat as a patient-centered treatment option for CKD-related anemia. Registration of clinical trials ClinicalTrials.gov Identifier: NCT03350321 (November 22, 2017). ClinicalTrials.gov Identifier: NCT03350347 (November 22, 2017).

show abstract

Section: Methodsmentioning

confidence: 99%

Treatment satisfaction with molidustat in CKD-related anemia in non-dialysis patients: a post-hoc analysis of two clinical trials

et al. 2023

View full text Add to dashboard Cite

show abstract

“…In both trials, patients (who had received a study treatment at least once) were asked to complete the TSQM-II at baseline, week 12, and week 24 (Figure 1). The TSQM-II is an 11-item, self-administered, psychometrically valid measure of patient-reported satisfaction with medication [16] that has demonstrated validity and reliability among Japanese patients with chronic disease [17]. The TSQM-II contains four domains: effectiveness, side effects, convenience and global satisfaction.…”

Section: Methodsmentioning

confidence: 99%

Treatment satisfaction with molidustat in CKD-related anemia in non-dialysis patients

Yamamoto

Yamada

Miyazaki

et al. 2022

Preprint

View full text Add to dashboard Cite

Erythropoiesis-stimulating agents (ESAs) are a standard treatment for patients with renal anemia to increase hemoglobin (Hb) levels and reduce their need for blood transfusions. However, treatments targeting high Hb levels require high doses of ESAs by the intravenous injection which are associated with an elevated risk of adverse cardiovascular events. In response to this key limitation other erythropoietin-promoting medications have been developed such as hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PH inhibitor). This post-hoc analysis of two clinical trials evaluates patients’ treatment satisfaction with a HIF-PH inhibitor, molidustat, compared to a standard ESA, darbepoetin alfa, as part of therapy for patients with non-dialysis chronic kidney disease (CKD) and renal anemia. Exploratory outcome data using the Treatment Satisfaction Questionnaire for Medicine version II (TSQM-II) showed that both arms in both trials had increased treatment satisfaction over the course of the study period as well as improvements in most TSQM-II domains at week 24. Molidustat was associated with convenience domain scores at multiple timepoints depending on the trial and more patients were highly satisfied with the convenience of molidustat compared to darbepoetin alfa. Patients treated with molidustat also had increases in global satisfaction domain scores compared to darbepoetin alfa, but the differences s in global satisfaction domain scores were not significant. These patient-reported satisfaction outcomes provide findings supporting the use of molidustat as a patient-centered treatment option for CKD-related anemia.

show abstract

“…Numerous studies were conducted worldwide on the validity and reliability of the TSQM questionnaire (6,(9)(10)(11)(12). A study conducted in the United States on eight different groups of patients showed that the reliability coefficient was acceptable with Cronbach's alpha coefficient of the questionnaire, and therefore this questionnaire could be a good predictor of drug treatment in different patients (6).…”

Section: Introductionmentioning

confidence: 99%

Treatment Satisfaction Questionnaire for Medication (TSQM Version II): A Psychometric Properties Analysis

Shahrbabaki¹,

Ahmadipour²,

Yousefi³

et al. 2022

Int J High Risk Behav Addict

View full text Add to dashboard Cite

Background: Methadone or buprenorphine maintenance therapy is an effective treatment for opioid dependence. Since the satisfaction of patients under methadone maintenance treatment (MMT) plays an important role in their therapeutic success, it seems important to evaluate the satisfaction of methadone usage using multidimensional psychometric tools. Objectives: The current study aimed to investigate the psychometric properties of the Persian version of the Treatment Satisfaction Questionnaire for Medication (TSQM) version II. Patients and Methods: This cross‑sectional study was carried out on 288 opioid-dependent patients of Shahid Beheshti MMT clinic in Kerman, Iran, selected using the convenience sampling method. The data were collected using a questionnaire containing the demographic characteristics of the participants and the Persian version of the TSQM version II containing 11 items in four subscales of effectiveness, side effects, the convenience of use, and overall satisfaction. The sum of the scores of each subscale is displayed as a number from 0 to 100. The face and content validity of the questionnaire was confirmed. The construct validity was assessed using exploratory factor analysis (EFA) and confirmatory factor analysis (CFA). The internal consistency and repeatability of the TSQM version II were determined using Cronbach’s alpha and test-retest methods, respectively. LISREL software (version 8.8) and SPSS software (version 20.0) were used to analyze the data. Results: The sample with the male majority of 85% had a mean age of 46.24 ± 11.5 years. As a measure of internal consistency, Cronbach’s alpha of the Persian version of the TSQM version II was 0.8. The repeatability of the questionnaire using the test-retest method was calculated at 0.9. The EFA revealed the adequacy of sampling and justifiability of the analysis (Kaiser‑Meyer‑Olkin = 0.82, P = 0.001, χ2 = 1507.02, df = 28). In CFA, the goodness of fit was at an appropriate level. Conclusions: The TSQM Persian version can be used as an effective and consistent tool to assess treatment satisfaction in clinical settings.

show abstract

Psychometric validation of anti-clot treatment scale and treatment satisfaction questionnaire for medication version II in Japanese patients with atrial fibrillation

Cited by 3 publications

References 33 publications

Treatment satisfaction with molidustat in CKD-related anemia in non-dialysis patients: a post-hoc analysis of two clinical trials

Treatment satisfaction with molidustat in CKD-related anemia in non-dialysis patients: a post-hoc analysis of two clinical trials

Treatment satisfaction with molidustat in CKD-related anemia in non-dialysis patients

Treatment Satisfaction Questionnaire for Medication (TSQM Version II): A Psychometric Properties Analysis

Contact Info

Product

Resources

About